Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

Abstract

The combination of MART-1 peptide-pulsed DC and tremelimumab results in objective and durable tumor responses at the higher range of the expected response rate with either agent alone.